Skip to main content

Table 1 General characteristics of T2DM patients at baseline

From: The effects of taurine supplementation on oxidative stress indices and inflammation biomarkers in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

VariableTaurine group (n = 26)Placebo group (n = 24)P-value
Age (years)b42.04 ± 6.3744.17 ± 6580.252d
Sex (n/%)0.630c
Male (n/%)a7 (26.9)7 (33.3) 
Female (n/%)a19 (73.1)16 (66.7)
Duration of T2DM, yearsb3.85 ± 1.583.25 ± 1.300.212d
Family history of diabetes (%)a11 (42.3)9 (37.5)0.828d
Metformin use, n (%)a24 (92.3)22 (91.7)0.935c
Glibenclamide use, n (%)a8 (30.8)6 (25)0.658c
Weight (kg)b80.21 ± 8.4978.90 ± 11.70.657d
BMI (kg/m2)b30.62 ± 3.9830.25 ± 2.660.699d
WC (cm)b100.53 ± 7.01101.25 ± 6.280.708d
FBS (mg/dL)b168.37 (16.33)174.22 (19.79)0.259d
HbA1C,  %b6.97 (0.71)7.26 (0.91)0.215d
Insulin, mU/mLb10.66 (3.17)11.70 (3.60)0.340d
Physical activity
Low (%)a11 (42.3)14 (58.3)0.511
Moderate (%)a14 (53.8)8 (33.3)
High (%)a1 (4.3)2 (8.3)
  1. T2DM: Type 2 Diabetes Mellitus; BMI: Body Mass Index; WC: Waist Circumference; FBS: Fasting Blood Sugar
  2. aValues are expressed as frequency (%)
  3. bValues are expressed as mean (SD)
  4. cChi square test
  5. dIndependent samples t-test